[HTML][HTML] Molecular pathways and targets in prostate cancer
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression.
The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous …
The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous …
Overcoming drug resistance and treating advanced prostate cancer
J Semenas, C Allegrucci, SA Boorjian… - Current drug …, 2012 - ingentaconnect.com
Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant
prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone …
prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone …
Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules
Cancer stem-like cells (CSCs) are rare subpopulations of cancer cells that are reported to be
responsible for cancer resistance and metastasis associated with conventional cancer …
responsible for cancer resistance and metastasis associated with conventional cancer …
[HTML][HTML] Therapy escape mechanisms in the malignant prostate
Androgen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches
for AR inactivation include chemical castration, inhibition of androgen synthesis and AR …
for AR inactivation include chemical castration, inhibition of androgen synthesis and AR …
Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts
A Prajapati, S Gupta, B Mistry… - BioMed research …, 2013 - Wiley Online Library
Benign Prostate hyperplasia (BPH) and prostate cancer (PCa) are the most common
prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance …
prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance …
Glycosylation is a global target for androgen control in prostate cancer cells
J Munkley - Endocrine-Related Cancer, 2017 - erc.bioscientifica.com
Prostate cancer (PCa) is one of the most common causes of male cancer-related death in
Western nations. The cellular response to androgens is mediated via the androgen receptor …
Western nations. The cellular response to androgens is mediated via the androgen receptor …
The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate …
Abstract Background Prostate cancer (PCa) is one of the most frequently diagnosed tumors
in men. In general, therapies for localized PCa are curative. However, treatment of advanced …
in men. In general, therapies for localized PCa are curative. However, treatment of advanced …
Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer
J Cui, Y Wang, B Dong, L Qin, C Wang… - … Journal of Cancer, 2018 - Wiley Online Library
Although androgen deprivation therapy (ADT) is a standard treatment for metastatic prostate
cancer, this disease inevitably recurs and progresses to ADT‐resistant stage after this …
cancer, this disease inevitably recurs and progresses to ADT‐resistant stage after this …
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells
ES Polson, JL Lewis, H Celik, VM Mann… - Nature …, 2013 - nature.com
While chromosomal translocations have a fundamental role in the development of several
human leukaemias, their role in solid tumour development has been somewhat more …
human leukaemias, their role in solid tumour development has been somewhat more …
Advanced prostate cancer—a case for adjuvant differentiation therapy
JK Rane, D Pellacani, NJ Maitland - Nature reviews Urology, 2012 - nature.com
The development of novel therapies such as abiraterone acetate and sipuleucel-T has
improved the outlook for patients with advanced-stage and castration-resistant prostate …
improved the outlook for patients with advanced-stage and castration-resistant prostate …